[CAS NO. 73384-59-5] Ceftriaxone

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [73384-59-5]

Catalog

HY-B0712

Brand

MCE

CAS

73384-59-5

DESCRIPTION [73384-59-5]

Overview

MDL	-
Molecular Weight	554.58
Molecular Formula	C18H18N8O7S3
SMILES	O=C(C(N12)=C(CSC(N(C)NC3=O)=NC3=O)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O

For research use only. We do not sell to patients.

4 Publications Citing Use of MCE

Summary

Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic , which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC ₅₀ value of 0.78 mM. Ceftriaxone is an inhibitor of Aurora B . Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis ^[1] ^[2] ^[3] ^[4] ^[5] ^[6] ^[7] .

IC50 & Target

β-lactam

In Vitro

Ceftriaxone (100 μM, 24 h) protects MPP ⁺ treated astrocytes by inhibiting the NF-κB/JNK/c-Jun signaling pathway [3].
Ceftriaxone (500 μM, 24-48 h) effectively inhibits unanchored cell growth in A549, H520 and H1650 lung cancer cells by inhibiting Aurora B ^[4] .

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[3]

Cell Line:	Astrocyte
Concentration:	100 μM
Incubation Time:	24 h
Result:	Improved cell viability and increased glutamate uptake after MPP ⁺ expose.

Western Blot Analysis ^[3]

Cell Line:	Astrocyte
Concentration:	100 μM
Incubation Time:	24 h
Result:	Enhanced GLT-1 and GFAP expression. Decreased the expression of p-p50、p-IKKα、p-Relb. Decreased the number of TUNEL-positive cells.

In Vivo

Ceftriaxone (200 mg/kg Intraperitoneal injection for 6 weeks) improves functional markers and oxidative stress and inflammation parameters in a rat model of D-galactose (DGL) -induced liver and kidney injury ^[5] .
Ceftriaxone (200, 400 mg/kg, Intraperitoneal injection) has a protective effect on convulsion induced by Pentylenetetrazol (PTZ) and PTZ-related oxidative damage in rats ^[6] .
Ceftriaxone (100, 200 mg/kg, Intraperitoneal injection) reduces mechanical dysodynia and hyperalgesia by activating GLT-1 in Streptozocin ( HY-13753 )-induced diabetic rat models ^[7] .

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	DGL-induced rat model ^[5]
Dosage:	200 mg/kg
Administration:	i.p.
Result:	Reduced the BUN、Cr 、AST and ALT levels. Attenuated the MDA levels and enhanced GPx and CAT activities. Reduced the levels of IL-1β and TNF-α mRNA.

Animal Model:	PTZ-induced rat model ^[6]
Dosage:	200, 400 mg/kg
Administration:	i.p. 60 min before to PTZ (70 mg/kg)
Result:	Both of the two ceftriaxone groups had lower spike percentages than the saline group. Significantly lower MDA levels and higher SOD activity in 200 and 400 mg/kg.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03449940	Ministry of Health, Jamaica\|University Hospital of the West Indies	Erectile Dysfunction	January 2015	Not Applicable
NCT04141787	Vancouver Island Health Authority	Staphylococcal Infections\|Osteomyelitis\|CNS Infection\|Septic Arthritis\|Diabetic Foot Infection\|Vertebral Osteomyelitis\|Abscess\|Coagulase Negative Staphylococcal Infection	July 11, 2019	Phase 4
NCT00493220	Baxter Healthcare Corporation\|Halozyme Therapeutics	Healthy	June 2007	Phase 1
NCT00512616	National Institute of Mental Health (NIMH)\|National Institutes of Health Clinical Center (CC)	Bipolar Disorder	August 1, 2007	Phase 2
NCT02742948	Cairo University	Endometritis	April 2016	Phase 2
NCT01988428	Amsterdam UMC, location VUmc\|Stichting Nuts Ohra\|Nederlandse Internisten Vereniging ( Dutch Association of Internists)	Sepsis\|Severe Sepsis\|Septic Shock	June 2014	Not Applicable
NCT02328469	University Medical Centre Ljubljana\|Slovenian Research Agency\|University of Ljubljana School of Medicine, Slovenia\|Harvard University	Aseptic Meningitis	June 2014
NCT01723150	National University Hospital, Singapore\|Tan Tock Seng Hospital\|Singapore General Hospital	Liver Abscess, Pyogenic	November 5, 2013	Phase 4
NCT02567825	Alejandro Hoberman\|George Washington University\|National Institute on Deafness and Other Communication Disorders (NIDCD)\|University of Pittsburgh	Acute Otitis Media	November 2015	Not Applicable
NCT00449800	Association Pour La Promotion A Tours De La Reanimation Medicale	Sepsis\|Severe Sepsis\|Septic Shock	July 2006	Phase 4
NCT01421693	Oxford University Clinical Research Unit, Vietnam\|University of Oxford\|Patan Academy of Health Sciences, Nepal\|Patan Hospital, Nepal\|Civil Hospital, Nepal	Enteric Fever\|Typhoid Fever	September 2011	Phase 4
NCT00566111	Yale University\|Stanley Medical Research Institute	Bipolar Depression	September 2007	Not Applicable
NCT00004216	Vion Pharmaceuticals\|National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	August 1999	Phase 1
NCT04839653	MEDSI Clinical Hospital 1, ICU	Pneumonia, Ventilator-Associated\|Pneumonia\|Bloodstream Infection\|Sepsis\|Respiratory Distress Syndrome\|Respiratory Tract Infections\|Critical Illness	May 1, 2021	Not Applicable
NCT03061604	Theodor Bilharz Research Institute\|Université Libre de Bruxelles	Variceal Hemorrhage	November 2014	Not Applicable
NCT00326287	Basilea Pharmaceutica	Pneumonia	June 2006	Phase 3
NCT05051163	Makerere University	HIV-1-infection\|Malnutrition, Child	June 14, 2021	Phase 2\|Phase 3
NCT00621504	Forest Laboratories	Bacterial Pneumonia	January 2008	Phase 3
NCT05079620	UConn Health	Aspiration\|Aspiration Pneumonia	November 30, 2021	Phase 4
NCT03959527	Global Antibiotics Research and Development Partnership	Gonorrhea	November 6, 2019	Phase 3
NCT04870138	National Institute of Allergy and Infectious Diseases (NIAID)	Gonococcal Infection	March 10, 2013	Phase 1
NCT00035347	Pfizer	Community-Acquired Pneumonia (CAP)	January 2001	Phase 4
NCT01163994	University Medical Centre Ljubljana	Multiple Erythema Migrans	June 2010	Not Applicable
NCT01265173	Korea University	SBP\|Liver Cirrhosis	April 2007	Phase 4
NCT00942006	University Medical Centre Ljubljana	Suspected Early Lyme Neuroborreliosis	July 2009	Not Applicable
NCT03794765	Postgraduate Institute of Medical Education and Research	Ulcerative Colitis\|Inflammatory Bowel Diseases\|Acute Severe Colitis	April 1, 2019	Phase 2
NCT01390623	University Hospital, Clermont-Ferrand	Acute Uncomplicated Pyelonephritis	July 2011	Phase 4
NCT01669980	Forest Laboratories	Infections\|Pneumonia	October 2012	Phase 4
NCT00001101	National Institute of Allergy and Infectious Diseases (NIAID)	Lyme Disease		Phase 3
NCT03179384	Centre Hospitalier Universitaire de Nice	Pyelonephritis Acute	June 26, 2017	Phase 4
NCT00230971	Wyeth is now a wholly owned subsidiary of Pfizer	Appendicitis\|Cholecystitis\|Diverticulitis\|Intra-Abdominal Abscess\|Intra-Abdominal Infection\|Peritonitis	October 2005	Phase 4
NCT00481702	Merck Sharp & Dohme LLC	Intra-abdominal Infection	December 2001	Phase 3
NCT00000648	National Institute of Allergy and Infectious Diseases (NIAID)\|Hoffmann-La Roche	HIV Infections\|Neurosyphilis		Not Applicable
NCT02142751	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla\|Spanish Network for Research in Infectious Diseases	Infection Due to ESBL Escherichia Coli	July 2014	Phase 3
NCT00111644	Hoffmann-La Roche	Pneumonia, Bacterial	March 2005	Phase 2
NCT05375240	Tianjin Medical University General Hospital	Stroke\|Cerebrovascular Disorders\|Ischemic Stroke\|Brain Diseases\|Central Nervous System Diseases\|Nervous System Diseases\|Cardiovascular Diseases\|Propranolol\|Beta Blocker\|Molecular Mechanisms of Pharmacological Action\|Immunologic Factors\|Physiological Effects of Drugs	June 2022	Phase 2
NCT05149287	Austin V Stone\|University of Kentucky	Meniscus Tear\|Meniscus Lesion\|Cartilage Injury	December 28, 2021	Phase 2
NCT04771884	Shandong University\|Children´s Hospital of Chongqing Medical University	Bacterial Meningitis\|Augmented Renal Clearance	October 1, 2020
NCT03560232	Mercy Health Ohio	Open Fracture\|Post-Op Wound Infection	July 9, 2018	Phase 4
NCT01150747	Harold Wiesenfeld\|National Institute of Allergy and Infectious Diseases (NIAID)\|University of Pittsburgh	Chlamydia	January 2011
NCT00431678	Bayer	Pneumonia	January 2004	Phase 3
NCT00037479	National Institute of Neurological Disorders and Stroke (NINDS)	Lyme Disease\|Lyme Neuroborreliosis	December 1999	Phase 2
NCT00769171	Bayer	Infection, Intra-abdominal	October 2005	Phase 3
NCT04041791	University of Oxford\|University of Nairobi\|London School of Hygiene and Tropical Medicine\|National Institute for Health Research, United Kingdom\|Department for International Development, United Kingdom\|Medical Research Council\|Wellcome Trust\|Kenya Ministry of Health	Pneumonia	August 19, 2019	Phase 3
NCT02735707	UMC Utrecht\|Australian and New Zealand Intensive Care Research Centre\|Medical Research Institute of New Zealand\|Unity Health\|Berry Consultants\|Global Coalition for Adaptive Research\|University of Pittsburgh Medical Center\|Intensive Care National Audit & Research Centre\|St. Marianna University School of Medicine\|National Intensive Care Surveillance MORU	Community-acquired Pneumonia, Influenza, COVID-19	April 11, 2016	Phase 3
NCT01247909	Kamuzu University of Health Sciences	Infant Bacterial Meningitis	April 2010	Phase 4
NCT00910533	University Medical Centre Ljubljana	Nervous System Lyme Borreliosis	January 1, 2009	Not Applicable
NCT00914888	Wyeth is now a wholly owned subsidiary of Pfizer	Community Acquired Bacterial Pneumonia\|Complicated Intra-Abdominal Infection	January 2011	Phase 3
NCT05398081	Dr. Promise Tamunoipiriala Jaja\|University College Hospital, Ibadan	Surgical Site Infection\|Antibiotics Prophylaxis	December 1, 2021	Phase 2
NCT02015637	Melinta Therapeutics, Inc.	Gonorrhea	January 23, 2014	Phase 3
NCT01278017	Chang Gung Memorial Hospital	Diarrhea	August 2010	Phase 4
NCT03840811	National Institute of Allergy and Infectious Diseases (NIAID)	Gonococcal Infection	April 23, 2017	Phase 1
NCT04066621	Xiangbei Welman Pharmaceutical Co., Ltd	Respiratory Tract Infections\|Urinary Tract Infections in Children	April 28, 2015	Phase 4
NCT02257918	National Institute of Allergy and Infectious Diseases (NIAID)	Gonorrhoea	November 25, 2014	Phase 2
NCT01635530	Turku University Hospital	Lyme Neuroborreliosis	August 2012	Phase 4
NCT05216744	Haiphong University of Medicine and Pharmacy	Neisseria Gonorrhoeae Infection\|Chlamydia Trachomatis Infection	July 15, 2021	Phase 2
NCT02561442	scPharmaceuticals, Inc.	Pharmacokinetics in Healthy Adults	October 2015	Phase 2\|Phase 3
NCT01659866	Northwestern University	Infection	August 2012	Phase 4
NCT03012360	University Hospital, Lille\|Ministry of Health, France	Mechanical Ventilation Complication\|Critical Illness	February 8, 2018	Phase 4
NCT01371838	Pfizer\|Forest Laboratories	Community-Acquired Bacterial Pneumonia\|Lung Infection of Individual Not Recently Hospitalized	December 2011	Phase 3
NCT01757236	University Hospital, Tours\|Pfizer\|International Clinical Trials Association	Hip Prosthetic Joint Infection	October 2012	Phase 2
NCT00509106	Forest Laboratories	Bacterial Pneumonia	July 2007	Phase 3
NCT00895089	Kaohsiung Veterans General Hospital.\|Bayer	Liver Abscess	May 2009	Phase 4
NCT04218695	Beth Israel Deaconess Medical Center\|American Association for the Study of Liver Diseases Foundation	Cirrhosis, Liver	August 24, 2020	Phase 4
NCT01014013	Merck Sharp & Dohme LLC	Urinary Tract Infection	April 2008	Phase 3
NCT02210325	Melinta Therapeutics, Inc.\|National Institute of Allergy and Infectious Diseases (NIAID)	Uncomplicated Urogenital Gonorrhea	August 2014	Phase 3
NCT05943223	McMaster Children´s Hospital	Appendicitis Perforated	January 2024	Phase 2
NCT02424461	Assistance Publique - Hôpitaux de Paris	Acute Male Urinary Tract Infection	February 2015	Phase 3
NCT02473263	Assistance Publique - Hôpitaux de Paris	Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit	May 9, 2016	Phase 3
NCT02098486	Kangbuk Samsung Hospital	Cholangitis	March 2014	Phase 2
NCT05654896	Nadeem Iqbal\|Ahmad Zia\|Muhammad Junaid Tahir\|Pakistan Kidney and Liver Institute and Research Center	Antibiotic Prophylaxis	November 26, 2022	Phase 3
NCT00349622	Massachusetts General Hospital\|National Institute of Neurological Disorders and Stroke (NINDS)	Amyotrophic Lateral Sclerosis\|ALS	July 2006	Phase 3
NCT05294588	University of North Carolina, Chapel Hill\|National Institute of Allergy and Infectious Diseases (NIAID)	Gonorrhea Male	April 18, 2022	Phase 2
NCT00451386	Merck Sharp & Dohme LLC	Urinary Tract Infections\|Bacterial Pneumonia\|Soft Tissue Infections	January 2002	Phase 2
NCT03681431	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	Infectious Endocarditis	April 23, 2018	Phase 2
NCT03895567	University of Oxford\|Biopharma (Orofino Pharmaceuticals Group)	Healthy	June 2024	Phase 1
NCT01473836	Pfizer	Intra-abdominal Infections	November 2011	Phase 3
NCT05971550	Assistance Publique - Hôpitaux de Paris	Neisseria Gonorrhoeae Infection\|Asymptomatic Pharyngeal Carriage	September 2023	Phase 3
NCT02659033	Assistance Publique - Hôpitaux de Paris	Emergence of Bacterial Resistance to Antibiotics	March 2016	Phase 3
NCT04975945	The Grant Medical College & Sir J.J. Group of Hospitals	Surgical Wound Infection\|Surgical Site Infection	August 2021	Phase 4
NCT00161330	University of Padova\|Regione Veneto\|IL Sogno di Stefano	Urinary Tract Infections	June 2000	Phase 3
NCT02334124	Murdoch Childrens Research Institute	Cellulitis	January 2015	Not Applicable
NCT04202068	Xiangbei Welman Pharmaceutical Co., Ltd	Gonorrhea	July 3, 2015	Phase 4
NCT00358202	CPL Associates\|Elan Pharmaceuticals	Pneumonia	March 2002	Phase 4
NCT00797108	Pfizer	Pneumonia, Bacterial	January 2009	Phase 2
NCT05980871	National Taiwan University Hospital	Early Syphilis	March 10, 2023	Phase 4
NCT00000938	National Institute of Allergy and Infectious Diseases (NIAID)	Lyme Disease		Phase 3
NCT02746276	University of Oxford\|KEMRI-Wellcome Trust Collaborative Research Program\|Centre for Research in Therapeutic Sciences, Strathmore University, Nairobi Kenya\|University College, London\|Centre for Microbiology Research, Kenya Medical Research Institute\|Centre for Clinical Research, Kenya Medical Research Institute	Malnutrition	April 1, 2016	Phase 2
NCT05470517	Johns Hopkins All Children´s Hospital	Complicated Appendicitis\|Acute Appendicitis	January 5, 2023	Phase 2
NCT00429975	Hospital Mutua de Terrassa\|Fondo de Investigacion Sanitaria	Pneumonia, Pneumococcal	August 2004	Phase 4
NCT00374959	Hospital Universitario Principe de Asturias\|Hoffmann-La Roche	Pneumonia	October 2000	Phase 4
NCT03087656	University of Southern California	Cholangitis	March 29, 2017	Phase 4
NCT03068741	Dr. Damon Scales\|Canadian Institutes of Health Research (CIHR)\|Sunnybrook Research Institute\|Sunnybrook Health Sciences Centre	Severe Sepsis or Septic Shock	March 23, 2020	Phase 4
NCT02177994	Ain Shams Maternity Hospital	Infection of Cesarian Section Wound Following Delivery	September 2013	Phase 3
NCT00591318	Research Foundation for Mental Hygiene, Inc.\|National Alliance for Research on Schizophrenia and Depression\|New York State Psychiatric Institute	Psychosis\|Schizophrenia\|Schizoaffective Disorder	October 10, 2007	Phase 1\|Phase 2
NCT00138801	Sorlandet Hospital HF	Lyme Neuroborreliosis	March 2004	Phase 3
NCT03133637	University of Rochester	Jaundice and Sepsis in Neonates	March 2016
NCT02996656	Université de Montréal\|Stryker Trauma GmbH\|Hopital du Sacre-Coeur de Montreal	Propionibacterium Infection	December 2016	Not Applicable
NCT01530763	Forest Laboratories\|AstraZeneca	Infections\|Community Acquired Pneumonia	September 2012	Phase 2\|Phase 3
NCT01745679	Nantes University Hospital	Meningitis\|Neurological Infections	December 2012	Phase 4
NCT03294395	Public Health Service of Amsterdam\|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Gonorrhea	September 18, 2017	Phase 3
NCT01254344	Merck Sharp & Dohme LLC	Infection\|Surgical Site Infection	December 2010	Phase 3
NCT02384200	University of California, San Diego\|Mayo Clinic\|University of British Columbia\|The Cleveland Clinic\|Duke University\|Ohio State University\|Dartmouth-Hitchcock Medical Center\|Vanderbilt University\|New York University	Nephrolithiasis\|Urinary Tract Infections	March 2015	Phase 4
NCT01160640	Harold Wiesenfeld\|National Institute of Allergy and Infectious Diseases (NIAID)\|University of Pittsburgh	Pelvic Inflammatory Disease	November 2010	Phase 2
NCT00002052	University of Southern California\|NIH AIDS Clinical Trials Information Service	HIV Infections\|Salmonella Infections		Not Applicable
NCT01645735	Forest Laboratories\|AstraZeneca	Infections	October 2012	Phase 4
NCT03174236	University of Oxford\|University College, London\|London School of Hygiene and Tropical Medicine\|Swansea Trials Unit\|Kenya Medical Research Institute\|KEMRI-Wellcome Trust Collaborative Research Program	Malnutrition Severe\|Antibiotic Resistance\|Antibiotic Toxicity	September 4, 2017	Phase 3
NCT00372541	Makerere University	Pneumonia	September 2006	Phase 3
NCT02443285	Tanta University	Primary Bacterial Peritonitis	January 2015	Phase 3
NCT02473640	Theriva Biologics, Inc.	Healthy Volunteers With Ileostomy	June 2015	Phase 1\|Phase 2
NCT03903783	Groupe Hospitalier Paris Saint Joseph	Infection, Bacterial	April 30, 2019	Not Applicable
NCT00195351	Wyeth is now a wholly owned subsidiary of Pfizer	Appendicitis\|Cholecystitis\|Cross Infection\|Diverticulitis\|Peritonitis	September 2005	Phase 4
NCT04010539	GlaxoSmithKline	Gonorrhea	October 21, 2019	Phase 3
NCT00157898	Merck Sharp & Dohme LLC	Complicated Intra-abdominal Infection	January 2004	Phase 4
NCT03413384	BrainX Corporation\|Virginia Contract Research Organization Co., Ltd.	Parkinson´s Disease Dementia	February 15, 2019	Phase 2
NCT02224040	Sheba Medical Center	Typhoid Fever	August 2013	Phase 4
NCT01602874	Pfizer	Community Acquired Bacterial Pneumonia\|Complicated Intra-Abdominal Infection	January 2011	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 31.25 mg/mL ( 56.35 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.8032 mL	9.0158 mL	18.0317 mL
5 mM	0.3606 mL	1.8032 mL	3.6063 mL
10 mM	0.1803 mL	0.9016 mL	1.8032 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% Saline

Solubility: ≥ 2.5 mg/mL (4.51 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.51 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.51 mM); Clear solution

* All of the co-solvents are available by MedChemExpress (MCE).